[Current principles of treatment of acute nonlymphoblastic leukemia].
Present-day chemotherapy warrants complete remissions in 45-70% of patients with acute nonlymphoblastic leukemia. However, therapeutic policy at the stages of remission induction and residual disease remains disputable. The authors studied the role of 3 chemotherapy programs (7 + 3, 7 + 3 + vincristine, C-ROPM) in achievement of remission of acute leukemia and effects of long-term standard regimens of remission maintenance and bone marrow transplantation on long-term relapse-free survival of patients. The addition of vincristine to the program 7 + 3 failed to make remission more frequent and recurrence-free survival longer. C-ROMP program warranted remission in 70% of patients, this proportion being significantly higher than on programs 7 + 3 and 7 + 3 + vincristine. More intensive chemotherapy during remission induction resulted in a rise of 4-year recurrence-free survival from 12 to 44%. Bone marrow transplantation used for treatment intensification in remission increased 4-year recurrence-free survival compared to standard chemotherapy from 44 to 80%.
Moiseev
S I
SI
Abdulkadyrov
K M
KM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods
Sovremennye printsipy lecheniia ostrogo nelimfoblastnogo leĭkoza.